Nasus Pharma Moves Intranasal Epinephrine Toward Pivotal Trial After Positive Phase 2 Results

Nasus Pharma Ltd. ( (NSRX) ) has provided an announcement.

Nasus Pharma Ltd., a clinical-stage developer of intranasal powder therapies, is leveraging its proprietary powder-based intranasal technology to deliver rapid, needle-free treatments for acute conditions such as anaphylaxis. The company’s lead candidate, NS002, aims to provide a convenient alternative to traditional epinephrine autoinjectors by exploiting the nasal cavity’s vascular network for fast systemic delivery.

On March 25, 2026, Nasus Pharma reported positive Phase 2 topline data for NS002 showing faster early epinephrine absorption than EpiPen and announced plans to initiate a pivotal study in the fourth quarter of 2026. The company also filed its 2025 annual report, detailed a wider pipeline including preclinical intranasal candidates NS003, NS004 and NS005, and highlighted a strengthened cash position following its IPO and a February 2026 private placement that is expected to fund operations through at least the second quarter of 2027, underscoring both increased R&D spend and a widened net loss as it scales as a newly public issuer.

The most recent analyst rating on (NSRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.

More about Nasus Pharma Ltd.

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company developing intranasal powder therapies for acute medical conditions in community settings. Its lead candidate, NS002, is an intranasal epinephrine powder positioned as a needle-free alternative to autoinjectors for anaphylaxis, built on a proprietary powder-based intranasal platform designed for rapid and reliable drug absorption.

Average Trading Volume: 164,219

Technical Sentiment Signal: Strong Sell

For an in-depth examination of NSRX stock, go to TipRanks’ Overview page.